Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  The Medicines Company    MDCO

THE MEDICINES COMPANY

(MDCO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2019 12/06/2019 12/09/2019 12/10/2019 12/11/2019 Date
83.9(c) 84.21(c) 84.15(c) 84.22(c) 84.07(c) Last
4 806 161 3 003 132 3 169 068 3 283 784 4 261 457 Volume
-0.20% +0.37% -0.07% +0.08% -0.18% Change
More quotes
Financials (USD)
Sales 2019 1,37 M
EBIT 2019 -208 M
Net income 2019 -261 M
Debt 2019 616 M
Yield 2019 -
Sales 2020 32,7 M
EBIT 2020 -256 M
Net income 2020 -309 M
Debt 2020 748 M
Yield 2020 -
P/E ratio 2019 -25,3x
P/E ratio 2020 -22,9x
EV / Sales2019 5 354x
EV / Sales2020 228x
Capitalization 6 721 M
More Financials
Company
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic... 
Sector
Pharmaceuticals
Calendar
02/19Earnings Release
More about the company
Surperformance© ratings of The Medicines Company
Trading Rating : Investor Rating :
More Ratings
Latest news on THE MEDICINES COMPANY
12/02Monteverde & Associates PC Announces an Investigation of THE MEDICINES COMPAN..
PR
11/26WeissLaw LLP Investigates The Medicines Co.
PR
11/25World share markets rally on revived trade hopes; dollar gains
RE
11/25World share markets rally on revived trade hopes; dollar gains
RE
11/25THE MEDICINES COMPANY ALERT : Bragar Eagel & Squire, P.C. Investigates the Propo..
PR
11/25EUROPE : Transatlantic dealmaking sends European shares back to four-year peak
RE
11/25The Medicines Co. Shares Up 23% on Novartis Buyout Offer
DJ
11/25BLACK FRIDAY FRENZY : Tiffany buys LVMH, Charles Schwab buys TD Ameritrade, Nova..
11/25(MDCO) ALERT : Johnson Fistel Investigates Proposed Sale of The Medicines Compan..
PR
11/25ALNYLAM PHARMACEUTICALS : Announces 2020 Product and Pipeline Goals and Provides..
AQ
11/25MEDICINES : Novartis to acquire The Medicines Company for USD 9.7 bn, adding inc..
AQ
11/25MEDICINES CO /DE : Entry into a Material Definitive Agreement, Financial Stateme..
AQ
11/25Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug make..
RE
11/25Novartis Expands Its Push Into Heart Drugs -- WSJ
DJ
11/25MEDICINES : What the other papers say this morning
AQ
More news
News in other languages on THE MEDICINES COMPANY
12/05EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Am..
11/26STOCK MARKET PARIS : Des marchés dopés à l'optimisme
11/25Point marchés-Les actions profitent des espoirs sur le commerce et des M&A
11/25LVMH et Novartis, très chères transactions ?
11/25WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on THE MEDICINES COMPANY
More recommendations
Sector news : Generic Pharmaceuticals
12/11BRISTOL MYERS SQUIBB : On Pace for Highest Close in Over a Year -- Data Talk
DJ
12/11DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
12/11ALLERGAN : Form 8.3 -
DJ
12/11ABBVIE : Form 8.3 -
DJ
12/11INTEC PHARMA : Says Novartis Ends Development Agreement
DJ
More sector news : Generic Pharmaceuticals
Chart THE MEDICINES COMPANY
Duration : Period :
The Medicines Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE MEDICINES COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 80,64  $
Last Close Price 84,07  $
Spread / Highest target 13,0%
Spread / Average Target -4,08%
Spread / Lowest Target -40,5%
EPS Revisions
Managers
NameTitle
Clive A. Meanwell Chief Innovation Officer & Director
Mark Timney Chief Executive Officer & Director
Alexander John Denner Chairman
Christopher Visioli Chief Financial Officer & Treasurer
John C. Kelly Independent Director
Sector and Competitors